Non-Small Cell Lung Cancer (NSCLC)

Treatment with THIO/cemiplimab was generally well-tolerated among patients with advanced NSCLC in the phase 2 THIO-101 study.

Glycan editing of cell surface glycans with E-602 may represent a novel therapeutic approach among patients with cancer.

Detection of S15 and PD-L1 proteins in more than half of NSCLC samples support the potential to target both pathways during treatment.

Updated OS findings from the PERLA trial showed continued success with dostarlimab plus chemotherapy in patients with advanced non–small cell lung cancer.

Treatment with domvanalimab/zimberelimab also improved progression-free survival vs platinum-based chemotherapy in the phase 3 ARC-10 study.

Patients with non–small cell lung cancer had a positive long-term benefit with perioperative chemoimmunotherapy, according to the 5-year NADIM trial update.

Data from the AcceleRET-Lung trial show an imbalanced risk of severe and fatal infection with pralsetinib for patients with RET fusion-positive NSCLC.

Phase 1 expansion data may support potential combination development for IDE397 in NSCLC and urothelial cancer harboring MTAP deletions.

Experts discussed the efficacy and durability of immunotherapy responses in patients with NSCLC.

A panel of experts focused on the use of dual immunotherapy options for patients with metastatic NSCLC without driver mutations.

Experts in non–small cell lung cancer met to debate the latest advances and treatment options and the hottest topics in the space.

Jenan Dailey, PharmD, BCAP, spoke about the approval of lazertinib plus amivantamab as first-line treatment for patients with locally advanced or metastatic NSCLC.

The agency places a partial clinical hold on the phase 3 PRESERVE-003 trial due to varying results between the squamous and nonsquamous NSCLC cohorts.

Data from the phase 2 SAVANNAH trial may support savolitinib as a new treatment option following standard-of-care osimertinib in EGFR-mutated NSCLC.

Support for the approval comes from phase 3 LUNAR study findings indicating TTFields significantly prolonged OS compared with standard of care alone.

Patients with non–small cell lung cancer and larger brain metastases may benefit most from the addition of up-front stereotactic radiosurgery to TKIs.

Results from KEYNOTE-671 show an improvement in OS when a neoadjuvant/adjuvant regimen of pembrolizumab was used to treat patients with NSCLC.

Data from the LUMINOSITY trial support the application for telisotuzumab vedotin in nonsquamous NSCLC harboring c-Met protein overexpression.

Findings from the phase 3 CheckMate 77T trial support the approval of nivolumab plus chemotherapy for resectable NSCLC.

The University of Chicago goes against Northwestern Medicine to see who will be crowned the winner in the NSCLC debate.

Experts discussed the advancements in non–small cell lung cancer treatment and developments in both antibody-drug conjugate–based approaches and targeted therapies.

Findings from the phase 3 LAURA trial support the approval of osimertinib for advanced EGFR-mutated NSCLC.

Results from the MARIPOSA-2 trial led to the approval of amivantamab plus chemotherapy in patients with EGFR-mutated NSCLC.

HERTHENA-Lung02 investigators will present further data from the trial at a future medical meeting.

A median EFS of 40.1 months was noted in patients resectable NSCLC given perioperative nivolumab vs placebo.

Superior efficacy outcomes were noted when adagrasib was used to treat patients with KRAS G12C NSCLC and among those with brain metastases.

The safety profile of nivolumab/relatlimab/chemotherapy in RELATIVITY-104 was comparable with prior reports of each individual agent.

Amivantamab plus chemotherapy also improved time to symptomatic progression among patients enrolled on the MARIPOSA-2 trial.

Data from the GALAXIES-Lung 201 trial found efficacy improvement in patients with advanced NSCLC.

Patients with NSCLC across various subgroups did not see a disease-free survival benefit with adjuvant durvalumab compared with placebo.